(+)-(5S)-1-(4,5-diphenyloxazol-2-yl)-5-(3-methoxybenzyl)cyclopentene | 171046-58-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (+)-(5S)-1-(4,5-diphenyloxazol-2-yl)-5-(3-methoxybenzyl)cyclopentene
• 英文别名: (+)-1-(4,5-diphenyloxazol-2-yl)-5(S)-(3-methoxybenzyl)cyclopentene；2-[(5S)-5-[(3-methoxyphenyl)methyl]cyclopenten-1-yl]-4,5-diphenyl-1,3-oxazole
• CAS: 171046-58-5
• 化学式: C₂₈H₂₅NO₂
• 分子量: 407.512
• InChiKey: JOOLIWQIOVEKTG-QHCPKHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (+)-(5S)-1-(4,5-diphenyloxazol-2-yl)-5-(3-methoxybenzyl)cyclopentene 在 palladium on activated charcoal 氢气 、 三溴化硼 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 3-[(1S,2S)-2-(4,5-Diphenyl-oxazol-2-yl)-cyclopentylmethyl]-phenol
  参考文献：
  名称：

  Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: Orally active prostacyclin mimetics. Part 6

  摘要：

  The synthesis and biological activity of novel derivatives of our previously reported IP receptor agonist FR181157 is described. SAR studies to replace the cyclohexene-linker of FR181157 led to the discovery of compound 1i (FR207845) as a potent non-prostanoid PGI(2) mimetic with good oral bioavailability. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.076
• 作为产物：
  描述：

  (S)-5-(3-Methoxy-benzyl)-cyclopent-1-enecarbonyl chloride 在 吡啶 、 ammonium acetate 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 生成 (+)-(5S)-1-(4,5-diphenyloxazol-2-yl)-5-(3-methoxybenzyl)cyclopentene
  参考文献：
  名称：

  Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: Orally active prostacyclin mimetics. Part 6

  摘要：

  The synthesis and biological activity of novel derivatives of our previously reported IP receptor agonist FR181157 is described. SAR studies to replace the cyclohexene-linker of FR181157 led to the discovery of compound 1i (FR207845) as a potent non-prostanoid PGI(2) mimetic with good oral bioavailability. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.076

文献信息

• 4,5-diaryloxazole derivatives
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06025375A1

  公开（公告）日：2000-02-15

  Heterocyclic compounds of the formula: ##STR1## whereinR.sup.1 is carboxy or protected carboxy, R.sup.2 is aryl which may have suitable substituent(s), R.sup.3 is aryl which may have suitable substituent(s), A.sup.1 is lower alkylene, A.sup.2 is bond or lower alkylene and -Q- is ##STR2## etc., and pharmaceutically acceptable salts thereof which are useful as a medicament.

  式为：##STR1##其中R.sup.1是羧基或保护羧基，R.sup.2是芳基，可能有适当的取代基，R.sup.3是芳基，可能有适当的取代基，A.sup.1是较低的烷基，A.sup.2是键或较低的烷基，-Q-是##STR2##等，以及其药学上可接受的盐，可用作药物。
• 4,5-DIARYLOXAZOLE DERIVATIVES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0736018B1

  公开（公告）日：2000-07-05
• OXAZOLE COMPOUNDS USEFUL AS PGE2 AGONISTS AND ANTAGONISTS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0989975A1

  公开（公告）日：2000-04-05
• US6025375A
  申请人：——

  公开号：US6025375A

  公开（公告）日：2000-02-15
• US6245790B1
  申请人：——

  公开号：US6245790B1

  公开（公告）日：2001-06-12